儿童C3肾小球病及相关疾病:病因-表型相关性与结局
该研究基于英国罕见肾病登记库(RaDaR),对80例儿童膜增生性肾小球肾炎(MPGN)/C3肾小球病进行详细表型分析和长期随访。中位随访5.18年,14%进展至肾衰竭;初始活检新月体>50%是唯一与肾衰竭独立相关的变量(HR 6.2,95%CI 1.05-36.6,P<0.05)。根据就诊时eGFR和新月体比例可划分三个预后组。
要点
- 儿童MPGN/C3肾小球病中,初始活检新月体>50%是肾衰竭的独立危险因素。
- 就诊时eGFR联合新月体比例有助于划分C3肾小球病的预后组。
- 获得性替代途径异常常见(46%),但并非肾衰竭的危险因素。
核心结论
- 新月体病变是儿童MPGN/C3肾小球病及免疫复合物GN进展至肾衰竭的关键危险因素。
- 就诊时eGFR和新月体病变有助于定义儿童C3肾小球病的预后分组。
- 获得性替代途径异常常见,但未显示为肾衰竭的危险因素。
研究设计与样本
- 基于英国国家罕见肾病登记库(RaDaR)的回顾性队列研究,纳入80例儿童MPGN/C3肾小球病患者。
- 所有患者接受详细表型分析和长期随访,中位随访5.18年(IQR 2.13-8.08)。
- 采用Cox比例风险模型分析肾脏生存危险因素,Kaplan-Meier法评估肾脏和移植肾存活。
主要发现
- 患者年龄2-15岁(中位9岁,IQR 7-11),中位补体C3和C4分别为0.31 g/L和0.14 g/L。
- 全部队列中46%检测到获得性(抗补体自身抗体)替代途径异常,9%检测到遗传性替代途径异常。
- 11例(14%)进展至肾衰竭,8例患者接受9次移植,其中2次因疾病复发失败。
- 多变量分析显示,初始活检新月体>50%是唯一与肾衰竭相关的变量(HR 6.2,95%CI 1.05-36.6,P<0.05)。
关键数值与推荐
- 初始活检新月体>50%与肾衰竭风险增加相关(HR 6.2,95%CI 1.05-36.6,P<0.05)。
- 根据就诊时eGFR和初始活检新月体>50%将C3肾小球病分为三个不同的预后组。
临床怎么用
- 儿童MPGN/C3肾小球病应重视初始肾活检新月体比例,>50%提示肾衰竭高风险。
- 结合就诊时eGFR和新月体病变可对患儿进行预后分层,指导随访强度。
- 获得性替代途径异常常见,但不应单独作为肾衰竭风险分层依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Membranoproliferative GN and C3 glomerulopathy are rare and overlapping disorders associated with dysregulation of the alternative complement pathway. Specific etiologic data for pediatric membranoproliferative GN/C3 glomerulopathy are lacking, and outcome data are based on retrospective studies without etiologic data. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 80 prevalent pediatric patients with membranoproliferative GN/C3 glomerulopathy underwent detailed phenotyping and long-term follow-up within the National Registry of Rare Kidney Diseases (RaDaR). Risk factors for kidney survival were determined using a Cox proportional hazards model. Kidney and transplant graft survival was determined using the Kaplan-Meier method. RESULTS: Central histology review determined 39 patients with C3 glomerulopathy, 31 with immune-complex membranoproliferative GN, and ten with immune-complex GN. Patients were aged 2-15 (median, 9; interquartile range, 7-11) years. Median complement C3 and C4 levels were 0.31 g/L and 0.14 g/L, respectively; acquired (anticomplement autoantibodies) or genetic alternative pathway abnormalities were detected in 46% and 9% of patients, respectively, across all groups, including those with immune-complex GN. Median follow-up was 5.18 (interquartile range, 2.13-8.08) years. Eleven patients (14%) progressed to kidney failure, with nine transplants performed in eight patients, two of which failed due to recurrent disease. Presence of >50% crescents on the initial biopsy specimen was the sole variable associated with kidney failure in multivariable analysis (hazard ratio, 6.2; 95% confidence interval, 1.05 to 36.6; P<0.05). Three distinct C3 glomerulopathy prognostic groups were identified according to presenting eGFR and >50% crescents on the initial biopsy specimen. CONCLUSIONS: Crescentic disease was a key risk factor associated with kidney failure in a national cohort of pediatric patients with membranoproliferative GN/C3 glomerulopathy and immune-complex GN. Presenting eGFR and crescentic disease help define prognostic groups in pediatric C3 glomerulopathy. Acquired abnormalities of the alternative pathway were commonly identified but not a risk factor for kidney failure.
引用
- Wong EKS, Marchbank KJ, Lomax-Browne H, et al. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes. Clin J Am Soc Nephrol. 2021. PMID: 34551983. doi:10.2215/CJN.00320121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。